From: info@breastadvocateapp.com A new study offers important information for patients considering breast reconstruction after mastectomy. Researchers compared immediate and delayed reconstruction using tissue from the patient’s own body. They found small differences in certain short-term complications. However, serious medical complications were rare in both groups. The findings can help patients and their surgical teams discuss the timing of reconstruction. Understanding …
What Mammogram Alternatives Are Available, and Do They Work?
From: healtine.com Mammography uses radiation to produce detailed images of the breasts. It’s one type of imaging test used in routine screening and to aid in the diagnosis of breast cancer. However, your doctor might recommend other tests depending on your medical history, how dense your breasts are, and personal preferences. Read on to learn more about different types of …
Scientists find breast cancer cells hiding behind protective “shields”
Source: Medical Research Council (MRC) Laboratory of Medical Sciences From: sciencedaily.com Scientists have uncovered hidden pockets of dormant breast cancer cells that may survive treatment behind a protective cellular shield and later trigger relapse. Credit: Shutterstock Researchers from the MRC Laboratory of Medical Sciences (LMS), Imperial College London, and UCL Genetics Institute have built a detailed cellular map of breast …
ASCO Guideline Update Recommends Risk-Based Breast Cancer Surveillance
From: targetedonc.com According to an updated guideline from the American Society of Clinical Oncology (ASCO), breast cancer follow-up and surveillance after primary treatment should be tailored to a patient’s individual risk of recurrence rather than a uniform, one-size-fits-all schedule.1 The guideline, accepted for publication in Journal of Clinical Oncology, stratifies patients into low-, intermediate-, and high-intensity surveillance groups based on …
5 Alarming Real-World Findings in HR-Positive, HER2-Low Metastatic Breast Cancer
From: oncodaily.com For patients with hormone receptor–positive metastatic breast cancer, the therapeutic landscape has expanded dramatically. CDK4/6 inhibitors transformed first-line treatment. Molecularly selected therapies targeting ESR1, PIK3CA and the AKT pathway have created additional endocrine-based options. And perhaps most importantly for HER2-low disease, antibody-drug conjugates have changed the meaning of HER2 expression itself. Yet real-world treatment often follows a more …
Baby Tam (Low-Dose Tamoxifen)
By: Jamie DiPolo From:.breastcancer.org Tamoxifen is commonly used to reduce the risk of invasive breast cancer or a recurrence of non-invasive disease if someone has been treated for DCIS, LCIS, or atypical ductal hyperplasia. But because of potential serious risks, including blood clots, endometrial cancer, and stroke, as well as troubling side effects, like hot flashes, many people either don’t …
Managing Breast Cancer Fatigue
From: healthline.com Fatigue is a common symptom of breast cancer and one of the most common side effects of breast cancer treatment. Studies suggest that 62% to 85%Trusted Source of people undergoing cancer treatment report having cancer-related fatigue. Those with breast cancer may be most affected by fatigue in the first 6 months following their diagnosis, reports a 2020 study. …
New Potential Target for Triple-Negative Breast Cancer
By: Dr. Chinta Sidharthan From: azolifesciences.com In a recent study published in Cell Death & Differentiation, researchers found that tumor-associated macrophages supply the molecular signal needed to recruit nerves into breast tumors. Background Triple-negative breast cancer lacks the hormone receptors that guide many other treatment strategies, leaving patients with fewer treatment options and a higher risk of relapse. The tumor …
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
From: .onclive.com The FDA has granted fast track designation to ETX-19477 for the treatment of adult patients with BRCA-mutated, hormone receptor (HR)–positive, HER2-negative unresectable or metastatic breast cancer.1 ETX-19477 is an oral, potent, and selective inhibitor of poly(ADP-ribose) glycohydrolase (PARG), is being evaluated as monotherapy in the phase 1/2 ERADIC8 trial (NCT06395519), which is enrolling phase 2 cohorts of patients …
Ask the Expert: What Are the Signs That Breast Cancer Is Returning?
From: healthline.com Oncology surgeon Elizabeth Berger, MD, MS, FACS answers common questions about breast cancer recurrence. Which types of breast cancer are most likely to recur? This depends upon many things. In general, triple-negative breast cancers and HER2-amplified breast cancers are most likelyTrusted Source to recur compared to luminal A breast cancers (estrogen receptor-positive, progesterone receptor-positive, and HER2-negative breast cancers), …